SepsisGLASSES-1NCT04141410
Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
An observational study of Sepsis and Septic Shock, run by Azienda USL Toscana Centro at 1 site in Italy.
Trial summary
Cardiogenic shock is a condition of low cardiac output that represents the end of a progressive deterioration of cardiac function. The main cause is ischemic heart disease but there are several causes of non-ischemic nature including sepsis. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Sepsis, Septic Shock, Cardiogenic Shock
- What is being tested?
- Levosimendan and Echocardiography
- Type of treatment
- Medical device
- How many people
- 35 participants
- Where
- 1 siteItaly
- Study dates
- 21 Oct 2019to 21 Jan 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Eligible patients will be those admitted to the intensive care units of the hospital Santo Stefano in Prato with diagnosis of cardiogenic shock during sepsis and who will present the following criteria for inclusion.
Who may be able to join
- Informed Consent
- Age between 18 and 80 years old
- Diagnosis di Sepsis following criteria of Third National Consensus Definitions for Sepsis and Septic Shock 2
- Diagnosis of Cardiogenic Shock with Heart Index < 2.5 L/min/m2 calculated by PiCCO thermodilution method and/or Diagnosis of Stroke Cardiogenic Shock Volume Index < 30 mL/beat/m2 calculated by PiCCO thermodilution method
- Patients applying for treatment with dobutamine and levosimendan according to the procedure laid down in current clinical practice at the Centre
- Ventricle coupling Arterial Ea/Ees > 1 via IElastance application
Who cannot join
- Age < 18 years and > 80 years
- Pre-existing diagnosis of heart failure at a reduced or preserved ejection fraction
- History of valvular heart disease or valve replacement and/or PM implant
- Severe pulmonary hypertension and chronic pulmonary heart
- Poor acoustic windows for echocardiography
- History of hypersensitivity or allergy to levosimendan
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
Ospedale Santo Stefano
Prato, FI, 59100
Iacopo Cappellini, MD, 3398921412, iacopo.cappellini@uslcentro.toscana.it
About this study
Official title: Levosimendan and Global Longitudinal Strain Assessment in Cardiogenic Shock Sepsis (GLASSES 1): a Study Protocol for an Observational Study
Cardiogenic shock is a condition of low cardiac output that represents the end of a progressive deterioration of cardiac function. The main cause is ischemic heart disease but there are several causes of non-ischemic nature including sepsis.
Sepsis is characterized by a picture of organ dysfunction caused by an altered response of the body to an infection. Its most serious form is septic shock, defined as a picture of sepsis in which the underlying abnormalities in the cardiovascular system and cellular metabolism are such as to increase mortality. An organ failure correlates directly with the function of others and this interdependence is especially evident when a cardiovascular failure is established. 3 Cardiac dysfunction in sepsis can be defined as that of a syndrome characterized by low cardiac output not related to myocardial ischemia.
Read more
The use of levosimendan in cardiogenic shock during sepsis was first described in a 2005 case report. Since then there have been small studies and other case reports that have shown improvements in right and left ventricular contractility, ventricular coupling, cardiopulmonary performance, global oxygen transport, renal and splanchnic perfusion when compared to dobutamine and placebo. Other beneficial effects of this drug have emerged, including an anti-inflammatory, antioxidant and antiapoptotic action with a possible protection from ischemia-reperfusion damage.
The present study aims to evaluate the correct use of levosimendan, after the occurrence of cardiogenic shock on a low cardiac index has been ascertained, with the aim of weaning from inotropic drugs in infusion.
Read the detailed description
The present is an observational single centre no profit study. The duration is expected to be 12 months from September 2019.
The study will be conducted by enrolling patients aged 18 to 80 years in intensive care with diagnosis of septic shock according to the Third National Consensus Definitions for Sepsis and Septic Shock2, with the need for infusion of vasoactive drugs to maintain a PAM > 65 mmHg. The following will be subjected to echocardiographic examination with Sparq ultrasound machine (Philips Healthcare, Best, the Netherlands) and 3.6 MHz cardiology probe through which will be acquired the apical projections 2, 3 and 4 chambers necessary to calculate the global longitudinal strain (GLS) through AutoSTRAIN© (TOMTEC Imaging Systems GmbH, Unterschleissheim, Germany).
During the echocardiographic examination, the Ea/Ees ratio (ventricle-arterial coupling) will also be calculated using the method modified on a single beat of Chen (t0) 18 using the IElastance® application. Patients will be monitored with the PiCCO® system (Pulse index Continuous Cardiac Output, Pulsion Medical systems, Munich, Germany) which measures the cardiac index (CI) and the Stroke Volume Index (SVI). Those with Ea//Ees > 1, cardiac index values < 2.5 L/min/m2 and/or Stroke Volume Index < 30 mL/beat/m2 will be considered eligible to enroll in the study. In these patients, dobutamine infusion will be started from 5 mcg/kg/min following the bundles of the Surviving Sepsis Campaign at dosages that allow to obtain an CI >2.5 L/min/m2 and/or Stroke Volume Index >30 mL/beat/m2. With 24 hours to go before the dobutamine infusion starts, CI and SVI will be recalculated using PiCCO®, GLS and ventricle-arterial coupling index by ultrasound investigation and then levosimendan infusion will begin for 24 hours starting with an infusion of 0.1 mcg/kg/min in order to wean the patient from dobutamine infusion. Once the infusion cycle of the calcium-sensitizing drug has been carried out, if possible, the infusion of dobutamine will be reduced until it stops and CI, SVI, GLS and Ea/Ees will also be re-evaluated. The same echocardiographic evaluations and hemodynamic calculations using PiCCO® will be performed 72 and 96 hours after the start of the dobutamine infusion. All patients enrolled will be followed up by a Medical Outcomes Survey Short-Form 36 (SF-36) questionnaire 28 days and 90 days after discharge from intensive care.
It should be noted that all the procedures described (including echocardiographic monitoring) comply in quantity and frequency with the normal practice of care and management of patients admitted to intensive care with diagnosis of cardiogenic shock during sepsis in Azienda USL Toscana Centro.
In addition, the parameters measured during the echocardiographic examination are derived from the reprocessing of the images collected during the examination and therefore simply represent an in-depth examination for diagnostic purposes performed according to current practice at the Centre.
- Conditions
- Sepsis, Septic Shock, Cardiogenic Shock
- Being tested
- Levosimendan, Echocardiography
- Keywords
- Sepsis, Septic Shock, Cardiogenic Shock, Speckle Tracking Echocardiography, Levosimendan
- Medical subject headings
- Sepsis, Shock, Septic, Shock, Cardiogenic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LevosimendanDrug
Use of Levosimendan in cardiogenic shock during sepsis
EchocardiographyDevice
Use of global longitudinal strain in cardiogenic shock during sepsis
What is being measured
The primary outcome is the main question the study is designed to answer.
Global Longitudinal Strain ≥ 15%
Recovery of normal values of GLS ≥ 15% after infusion of dobutamine and levosimendan
Measured: up to 1 week
Secondary outcomes (1)
Mortality
Mortality reduction 30% based on studies where GLS >-15% had half the mortality in those who had a value < 15%.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2019
- Study start21 Oct 2019
- Primary completion21 Oct 2020 (estimated)
- Study completion21 Jan 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SepsisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Azienda USL Toscana Centro
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Iacopo Cappellini, Azienda USL Toscana Centro
- Investigators
- Iacopo Cappellini, MD, Principal investigator, Azienda USL Toscana Centro
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04141410
- Sponsor's protocol ID
- 13875 17/18 PO
- Acronym
- GLASSES-1
- Status last verified
- Oct 2019
- First submitted
- 24 Oct 2019
- Last updated
- 28 Oct 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Cappellini I, Melai A, Zamidei L, Parise M, Cipani S, Consales G. Levosimendan and Global Longitudinal Strain Assessment in Sepsis (GLASSES 1): a study protocol for an observational study. BMJ Open. 2020 Sep 25;10(9):e037188. doi: 10.1136/bmjopen-2020-037188.
PubMed 32978191
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Levosimendan and Global Longitudinal Strain Assessment in Cardiogenic Shock Sepsis (GLASSES 1): a Study Protocol for an Observational Study
- ClinicalTrials.gov ID
- NCT04141410
- Acronym / sponsor ID
- GLASSES-1 / 13875 17/18 PO
- Conditions
- Sepsis, Septic Shock, Cardiogenic Shock
- Keywords
- Sepsis, Septic Shock, Cardiogenic Shock, Speckle Tracking Echocardiography, Levosimendan
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 35 participants (estimated)
- Lead sponsor
- Azienda USL Toscana CentroUniversity, hospital or other
- Study start
- 21 Oct 2019 (actual)
- Primary completion
- 21 Oct 2020 (estimated)
- Study completion
- 21 Jan 2021 (estimated)
- First posted
- 28 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardiogenic shock is a condition of low cardiac output that represents the end of a progressive deterioration of cardiac function. The main cause is ischemic heart disease but there are several causes of non-ischemic nature including sepsis.
Sepsis is characterized by a picture of organ dysfunction caused by an altered response of the body to an infection. Its most serious form is septic shock, defined as a picture of sepsis in which the underlying abnormalities in the cardiovascular system and cellular metabolism are such as to increase mortality. An organ failure correlates directly with the function of others and this interdependence is especially evident when a cardiovascular failure is established. 3 Cardiac dysfunction in sepsis can be defined as that of a syndrome characterized by low cardiac output not related to myocardial ischemia.
The use of levosimendan in cardiogenic shock during sepsis was first described in a 2005 case report. Since then there have been small studies and other case reports that have shown improvements in right and left ventricular contractility, ventricular coupling, cardiopulmonary performance, global oxygen transport, renal and splanchnic perfusion when compared to dobutamine and placebo. Other beneficial effects of this drug have emerged, including an anti-inflammatory, antioxidant and antiapoptotic action with a possible protection from ischemia-reperfusion damage.
The present study aims to evaluate the correct use of levosimendan, after the occurrence of cardiogenic shock on a low cardiac index has been ascertained, with the aim of weaning from inotropic drugs in infusion.
Detailed description
The present is an observational single centre no profit study. The duration is expected to be 12 months from September 2019.
The study will be conducted by enrolling patients aged 18 to 80 years in intensive care with diagnosis of septic shock according to the Third National Consensus Definitions for Sepsis and Septic Shock2, with the need for infusion of vasoactive drugs to maintain a PAM > 65 mmHg. The following will be subjected to echocardiographic examination with Sparq ultrasound machine (Philips Healthcare, Best, the Netherlands) and 3.6 MHz cardiology probe through which will be acquired the apical projections 2, 3 and 4 chambers necessary to calculate the global longitudinal strain (GLS) through AutoSTRAIN© (TOMTEC Imaging Systems GmbH, Unterschleissheim, Germany).
During the echocardiographic examination, the Ea/Ees ratio (ventricle-arterial coupling) will also be calculated using the method modified on a single beat of Chen (t0) 18 using the IElastance® application. Patients will be monitored with the PiCCO® system (Pulse index Continuous Cardiac Output, Pulsion Medical systems, Munich, Germany) which measures the cardiac index (CI) and the Stroke Volume Index (SVI). Those with Ea//Ees > 1, cardiac index values < 2.5 L/min/m2 and/or Stroke Volume Index < 30 mL/beat/m2 will be considered eligible to enroll in the study. In these patients, dobutamine infusion will be started from 5 mcg/kg/min following the bundles of the Surviving Sepsis Campaign at dosages that allow to obtain an CI >2.5 L/min/m2 and/or Stroke Volume Index >30 mL/beat/m2. With 24 hours to go before the dobutamine infusion starts, CI and SVI will be recalculated using PiCCO®, GLS and ventricle-arterial coupling index by ultrasound investigation and then levosimendan infusion will begin for 24 hours starting with an infusion of 0.1 mcg/kg/min in order to wean the patient from dobutamine infusion. Once the infusion cycle of the calcium-sensitizing drug has been carried out, if possible, the infusion of dobutamine will be reduced until it stops and CI, SVI, GLS and Ea/Ees will also be re-evaluated. The same echocardiographic evaluations and hemodynamic calculations using PiCCO® will be performed 72 and 96 hours after the start of the dobutamine infusion. All patients enrolled will be followed up by a Medical Outcomes Survey Short-Form 36 (SF-36) questionnaire 28 days and 90 days after discharge from intensive care.
It should be noted that all the procedures described (including echocardiographic monitoring) comply in quantity and frequency with the normal practice of care and management of patients admitted to intensive care with diagnosis of cardiogenic shock during sepsis in Azienda USL Toscana Centro.
In addition, the parameters measured during the echocardiographic examination are derived from the reprocessing of the images collected during the examination and therefore simply represent an in-depth examination for diagnostic purposes performed according to current practice at the Centre.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Eligible patients will be those admitted to the intensive care units of the hospital Santo Stefano in Prato with diagnosis of cardiogenic shock during sepsis and who will present the following criteria for inclusion.
Key inclusion criteria (6 listed)
- Informed Consent
- Age between 18 and 80 years old
- Diagnosis di Sepsis following criteria of Third National Consensus Definitions for Sepsis and Septic Shock 2
- Diagnosis of Cardiogenic Shock with Heart Index < 2.5 L/min/m2 calculated by PiCCO thermodilution method and/or Diagnosis of Stroke Cardiogenic Shock Volume Index < 30 mL/beat/m2 calculated by PiCCO thermodilution method
- Patients applying for treatment with dobutamine and levosimendan according to the procedure laid down in current clinical practice at the Centre
Key exclusion criteria (6 listed)
- Age < 18 years and > 80 years
- Pre-existing diagnosis of heart failure at a reduced or preserved ejection fraction
- History of valvular heart disease or valve replacement and/or PM implant
- Severe pulmonary hypertension and chronic pulmonary heart
- Poor acoustic windows for echocardiography
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LevosimendanUse of Levosimendan in cardiogenic shock during sepsis | Drug | – |
| EchocardiographyUse of global longitudinal strain in cardiogenic shock during sepsis | Device | – |
Primary outcome
Global Longitudinal Strain ≥ 15%
Time frame: up to 1 week
Recovery of normal values of GLS ≥ 15% after infusion of dobutamine and levosimendan
1 secondary outcome
Mortality
Time frame: 1 year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2019.
- Derived from this study: PubMed 32978191Cappellini I, Melai A, Zamidei L, Parise M, Cipani S, Consales G. Levosimendan and Global Longitudinal Strain Assessment in Sepsis (GLASSES 1): a study protocol for an observational study. BMJ Open. 2020 Sep 25;10(9):e037188. doi: 10.1136/bmjopen-2020-037188.
- Individual participant dataSharing planned: Yes
Related trials for Sepsis
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Not yet recruiting
Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)
Acute-on-Chronic Liver Failure (ACLF)
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Iacopo Cappellini, MD principal investigator
Azienda USL Toscana Centro
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sepsis and Septic Shock, run by Azienda USL Toscana Centro at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Iacopo Cappellini, MD (+393398921412, jacopocappellini@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Global Longitudinal Strain ≥ 15% (time frame: up to 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04141410, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2019.